EKF Diagnostics' Quo-Lab® HbA1c analyzer secures IFCC Certification

EKF Diagnostics, a global diagnostics company, is pleased to announce that its Quo-Lab® HbA1c point-of-care analyzer has successfully achieved International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certification.

The IFCC maintains the JCTLM (Joint Committee for Traceability in Laboratory Medicine) endorsed reference measurement procedure for HbA1c, which is accepted worldwide as the analytical control for the traceability of HbA1c measurement.

To participate in the program, manufacturers must register and report the results of twenty-four samples (two per month) across the measurement range. An IFCC Reference Laboratory supplies the samples.

“The awarding of this certification allows us to report results traceable to the IFCC reference method for quantitative determination of HbA1c,” said Gavin Jones, Diabetes Product Manager, EKF Diagnostics. “Together with the existing NGSP certification we achieved from 2012, the IFCC award demonstrates that Quo-Lab® meets all of the demanding standards set by independent certifying bodies.”

Glycated hemoglobin (HbA1c) testing is globally recognized as the gold standard in monitoring diabetic patients, enabling more complete disease management control. The Quo-Lab® analyzer offers laboratory-accurate results from just 4 µL of blood with a user-friendly interface, further simplifying the process.